SCHEMBL6509046

SCHEMBL6509046

Nc1cccc(-c2c(F)cccc2F)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.54
CYP3A4 P08684 2/20 0.48
CASP1 P29466 1/20 0.48
RECQL P46063 1/20 0.48
MAP4K4 O95819 4/20 0.46
METAP2 P50579 1/20 0.44
ENPP2 Q13822 1/20 0.44
MEN1 O00255 2/20 0.44
PSIP1 O75475 1/20 0.44
AXL P30530 1/20 0.44
MKNK1 Q9BUB5 1/20 0.44
MKNK2 Q9HBH9 1/20 0.44
ALOX5AP P20292 1/20 0.44
FEN1 P39748 1/20 0.44
TAAR1 Q96RJ0 1/20 0.42
BRD4 O60885 1/20 0.42
PDPK1 O15530 1/20 0.42
AURKA O14965 1/20 0.42
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30549059 1.00 MAOA (0.54) MAOACYP3A4CASP1RECQLMAP4K4
SCHEMBL3785823 0.90 MAOA (0.48) MAOACYP3A4CASP1RECQLMAP4K4
SCHEMBL29706653 0.89 MAOA (0.52) MAOACYP3A4CASP1RECQLMAP4K4
SCHEMBL25270075 0.87 MAOA (0.50) MAOACYP3A4CASP1RECQLMAP4K4
SCHEMBL12480139 0.86 MAOA (0.45) MAOACYP3A4CASP1RECQLMAP4K4
SCHEMBL8264667 0.85 MAOA (0.48) MAOACYP3A4CASP1RECQLMAP4K4
SCHEMBL9565253 0.83 TTR (0.46) MEN1ALOX5APFEN1TAAR1CA1
SCHEMBL12707386 0.82 MAOA (0.41) MAOACYP3A4CASP1RECQLMAP4K4
SCHEMBL3791191 0.78 MAOA (0.56) MAOACYP3A4CASP1RECQLMAP4K4
SCHEMBL251095 0.77 MAOA (0.83) MAOACYP3A4CASP1RECQLMAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230271936-A1 EFGR INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2023-08-31 US disclosed
US-20230271936-A1 EFGR INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2023-08-31 US disclosed
US-20230271936-A1 EFGR INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2023-08-31 US disclosed
EP-4194443-A1 EFGR INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2023-06-14 EP disclosed
EP-4194443-A1 EFGR INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2023-06-14 EP disclosed
WO-2005040152-A1 HETEROYCLYLPHENYL-AND HETEROCYCLYLPYRIDYL-SUBSTITUTED AZOLECARBOXAMIDES AS HERBICIDES E.I. DUPONT DE NEMOURS AND COMPANY (US) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271936-A1 EFGR INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF EGFR, WEE1, WEE2 MAOA 3060/4885CYP3A4 2692/4885CASP1 1097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.